With medical expertise persevering with to evolve and provide the most recent options and remedy to sufferers, Samsung Electronics Switzerland has been aiding the development by creating its merchandise.

 

Samsung collaborated with Bottneuro AG, a Swiss MedTech startup devoted to enhancing the prognosis and remedy of Alzheimer’s illness and to carry an progressive and enhanced diagnostic and remedy answer to sufferers. Bottneuro AG has chosen Samsung Galaxy Tab S8+ 5G Enterprise Version {hardware} to retailer and file remedy knowledge within the Bottneuro Answer.

 

 

Highly effective Remedy By Revolutionary Applied sciences

Bottneuro AG’s expertise identifies areas of the mind affected by the illness by means of 3D magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging knowledge. As soon as recognized, these areas may be focused and electronically stimulated with Miamind® neurostimulator expertise. The Galaxy Tab S8+ 5G Enterprise Version simplify dealing with the Bottneuro answer by way of a graphical interface.

 

Sufferers who are suffering from dementia usually expertise lowered cognitive perform within the early levels of the illness, making the necessity for locating a tool that’s simple to function and perceive crucial for Bottneuro AG. With its intuitive interface and usefulness, the Galaxy Tab S8+ 5G Enterprise Version offered the optimum {hardware} for the Bottneuro answer.

 

“We had been in search of a easy and dependable answer for our software. We discovered it with the Galaxy Tab S8+ 5G Enterprise Version and Samsung is giving us nice help within the growth,” stated Julius Klaas, CTO of Bottneuro AG.

 

 

Seamless Options in a Single Galaxy Pill

The Galaxy Tab S8+ 5G Enterprise Version presents a plethora of options and capabilities. It comes with a high-resolution Tremendous AMOLED show offering sensible readability for each sufferers and healthcare suppliers and presents dependable long-lasting battery life.

 

The Miamind® neurostimulator can also be instantly powered by the Galaxy Tab S8+ 5G Enterprise Version, and as soon as remedy is full, the Galaxy Tab S8+ routinely transmits diagnostic and remedy data contained inside the Bottneuro answer to Bottneuro AG by way of 5G knowledge connectivity, permitting sufferers to remain within the consolation of their residence. Moreover, the Galaxy Tab S8+ 5G Enterprise Version may be individually configured by means of Samsung Knox, conserving delicate knowledge and medical data non-public and guarded.

 

 

Partnerships for the Future

Groundbreaking improvements resembling these wouldn’t be attainable with out partnerships, and Samsung is proud to have been supporting and dealing with Bottneuro AG since its founding in 2021.

 

“We’re happy to supply Bottneuro AG a dependable, secure and easy answer with Samsung Knox and to help their novel remedy method,” added Daniele Casella, Head of MX B2B Cellular at Samsung Switzerland.

 

The effectiveness of Bottneuro AG’s new therapeutic remedy will probably be examined in a number of scientific research this 12 months. Whereas the remedy just isn’t commercially obtainable but, Bottneuro AG and Samsung stay optimistic about progress that may be made to deal with Alzheimer’s illness.

 

For extra data on Bottneuro AG and Samsung’s partnership, go to Samsung Newsroom Switzerland, www.bottneuro.com or www.miamind.com.